Insys Therapeutics (INSY) Return on Equity ROE from the first quarter 2019 to first quarter 2018 and annually, average high and low, overall ranking from Mar 31 2019 to Mar 31 2018 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Insys Therapeutics, Inc.  (INSY)

Insys Therapeutics's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Insys Therapeutics in the first quarter 2019?
Due to the lack of equity, it was not possible to calculate Insys Therapeutics, Inc.'s return on equity (ROE) in its first quarter 2019

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2019)
I. Quarter		 (Dec 31 2018)
IV. Quarter		 (Sep 30 2018)
III. Quarter		 (Jun 30 2018)
II. Quarter		 (Mar 31 2018)
I. Quarter
Y / Y Equity Change - - -99.87 % -90.75 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -228 -125 -124 -260 -241
Return On Equity (TTM) - -1558.04 % -351.49 % -420.74 % -197.02 %
INSY's Total Ranking # # # # #
Equity (TTM) in Millions -164 -43 0 25 50
Seq. Equity Change - - -99.44 % -51.01 % -24.04 %
Seq. Net Income Change - - - - -

Back to INSY Management Effectiveness >> INSY's 5 Years Annual ROE >> Compare INSY ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





INSY Annual Return On Equity (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015		 (Dec 31 2014)
2014
Total Equity in Millions -43 63 270 254 166
Y / Y Equity Change - -76.53 % 6.26 % 53.14 % 108.45 %
Net Income in Millions -125 -228 8 58 38
Y / Y Net Income Change - - -87.02 % 53.98 % -5.94 %
Return On Equity - -360.32 % 2.82 % 23.05 % 22.92 %

Back to INSY Management Effectiveness >> INSY's 5 Years Annual ROE >> Compare INSY ROE to its Competitors




Annual Roe Comment
In 2018 ROE improved to 22.92 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
INSY's' Return on Equity at Yahoo Finance
INSY's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for INSY's Competitors
Subscribers only: Roe for Insys Therapeutics's Suppliers
Subscribers only: Return On Equity for INSY's Customers




Companies with similar Return On Equity at Mar 31 2019, within Healthcare Sector ROE
Generex Biotechnology Corp  1,244.18 %
Zomedica Corp   1,110.36 %
Ampio Pharmaceuticals inc   758.28 %
Tuhura Biosciences Inc   439.58 %
Tenax Therapeutics Inc   263.35 %
Semler Scientific inc   191.29 %
Harrow Inc   168.50 %
Nrc Health  125.28 %
Zynex inc   106.15 %
Ligand Pharmaceuticals Incorporated  103.29 %

Date modified: 2026-09-12T06:13:29+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.